サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363066

網膜静脈閉塞症治療の市場規模、シェア、動向分析レポート：エンドユーザー別、疾患タイプ別、治療法別、地域別、セグメント予測、2023年～2030年

Retinal Vein Occlusion Treatment Market Size, Share & Trends Analysis Report By End-user (Retail Pharmacy, Hospital & Clinics), By Disease Type (CRVO, BRVO), By Treatment (Anti-VEGF, Corticosteroid Drugs), By Region, & Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 180 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
網膜静脈閉塞症治療の市場規模、シェア、動向分析レポート：エンドユーザー別、疾患タイプ別、治療法別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月18日
発行: Grand View Research
ページ情報: 英文 180 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

網膜静脈閉塞症治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の網膜静脈閉塞症治療市場規模は2030年までに41億8,000万米ドルに達し、2023年から2030年までのCAGRは6.92%で成長すると予測されています。

眼疾患の有病率の増加、老人人口の増加、眼疾患治療に対する意識の高まりが市場成長を後押しする主な要因です。既存製品や承認済み製品の存在、強力な製品パイプラインは、市場成長を促進すると予想される要因です。さらに、糖尿病とアテローム性動脈硬化症の有病率の増加は、RVOの有病率を増加させ、調査期間中の市場にプラスの影響を与える可能性があります。RVOに対する新薬の承認の増加は、調査期間中、市場に有利な機会を提供すると予想されます。

Samsung Bioepisは、黄斑浮腫、新生血管加齢黄斑変性、近視性脈絡膜新生血管、RVOなどの網膜疾患の治療薬として、初のバイオシミラー医薬品Byooviz（ranibizumab-nuna）を開発しました。2020年9月、この薬剤はFDAから商業化の承認を受けた。しかし、薬剤に関連する高額な費用が薬剤の処方を制限し、市場成長の妨げとなる可能性があります。BMC Ophthalmology誌に掲載された2021年の研究によると、ラニビズマブによる中心性RVO（CRVO）と分枝性RVO（BRVO）の治療には、中国では質調整生存年（QALY）当たり約449.17米ドルと454.75米ドルの費用がかかります。そのため、高い有効性と安全性を備えた手ごろな価格の薬剤のイントロダクションは、予測される期間中に市場に新たな成長機会をもたらすと期待されます。

さらに、糖尿病性網膜症、白内障、緑内障、加齢黄斑変性などの疾患が、世界的にこの疾患の主な原因となっています。高齢者人口の増加は、RVOに罹患する人々を比例して増加させています。加えて、ライフスタイルの変化により、心血管疾患や高血圧など、RVOを引き起こす様々な疾患の発生率も増加しています。ランセット・世界・ヘルス委員会（Lancet Global Health Commission）の世界の目の健康に関する報告書によると、2020年には世界で5億1,000万人が矯正されていない近見視力障害を、5億9,600万人が矯正されていない遠見視力障害を持つと推定されています。このように、二次的疾患の有病率の増加はRVOの有病率を高め、市場の成長を支える可能性があります。

網膜静脈閉塞症治療市場レポートハイライト

  • 疾患タイプ別では、効率的な治療のための研究開発活動や新規薬剤開発への投資が増加していることから、2022年にはブランチセグメントが市場を独占しました。
  • 治療薬別では、抗血管内皮増殖因子薬（抗VEGF薬）が、その安全性と第一選択薬としての普遍的な受容性により、2022年に最大シェアを占めました。
  • 小売薬局エンドユーザーセグメントは、薬の入手しやすさの向上や小売薬局を通じたRVOの利用可能な選択肢などの要因により、2022年に最大のシェアを占めました。
  • 北米は2022年に41.2%のシェアを獲得し、地域別で確固たる地位を確立しました。これは、同地域の政府資金増加による広範な研究開発活動と治療法の高い採用率の結果です。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

  • 市場セグメンテーションと範囲
  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
  • 市場促進要因
    • 網膜疾患の有病率の増加
    • 高齢者人口の増加
    • 強力な製品ポートフォリオの存在
  • 市場抑制要因分析
    • この病気に対する認識の欠如と過少診断
    • 治療費が高額になる
  • 事業環境分析
    • SWOT分析;要因別（政治・法律、経済・技術）
    • ポーターのファイブフォース分析
    • COVID-19感染症の影響分析

第4章 疾患別ビジネス分析

  • 網膜静脈閉塞症治療市場：病型変動分析
  • 網膜中心静脈閉塞症（CRVO）
  • 網膜静脈分枝閉塞症（BRVO）

第5章 治療別ビジネス分析

  • 網膜静脈閉塞症治療市場：治療変動分析
  • 抗血管内皮増殖因子（抗VEGF）
  • コルチコステロイド薬
  • その他

第6章 エンドユーザー別ビジネス分析

  • 網膜静脈閉塞症治療市場：エンドユーザーの変動分析
  • 病院とクリニック
  • 小売薬局
  • その他

第7章 地域別ビジネス分析

  • 地域別の網膜静脈閉塞症治療市場シェア、2022年および2030年
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第8章 競合情勢

  • 参入企業の概要
  • 財務実績
  • 参入企業
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 3 Global Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 4 Global Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 5 Global Retinal Vein Occlusion Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 6 North America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 7 North America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 8 North America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 9 North America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 10 U.S. Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 12 U.S. Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 13 Canada Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 15 Canada Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 16 Europe Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 18 Europe Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 19 Europe Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 20 Germany Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 22 Germany Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 23 UK Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 24 UK Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 25 UK Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 26 France Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 27 France Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 28 France Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 29 Italy Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 30 Italy Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 31 Italy Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 32 Spain Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 33 Spain Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 34 Spain Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 35 Denmark Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 36 Denmark Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 37 Denmark Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 38 Sweden Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 39 Sweden Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 40 Sweden Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 41 Norway Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 42 Norway Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 43 Norway Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 48 China Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 49 China Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 50 China Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 51 Japan Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 52 Japan Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 53 Japan Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 54 India Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 55 India Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 56 India Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 57 South Korea Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 58 South Korea Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 59 South Korea Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 60 Australia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 61 Australia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 62 Australia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 63 Thailand Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 64 Thailand Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 65 Thailand Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 66 Latin America Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 67 Latin America Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 68 Latin America Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Latin America Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 70 Brazil Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 71 Brazil Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 72 Brazil Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 73 Mexico Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 74 Mexico Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 75 Mexico Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 76 Argentina Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 77 Argentina Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 78 Argentina Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 83 South Africa Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 84 South Africa Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 85 South Africa Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 89 UAE Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 90 UAE Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 91 UAE Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)
  • Table 92 Kuwait Retinal Vein Occlusion Treatment Market, by Disease Type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Retinal Vein Occlusion Treatment Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Retinal Vein Occlusion Treatment Market, by End-user, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Retinal Vein Occlusion Treatment Market Segmentation
  • Fig. 8 Market Snapshot, 2022
  • Fig. 9 Market Trends & Outlook
  • Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Global Retinal Vein Occlusion Treatment Market: Disease Type Movement Analysis
  • Fig. 15 Global Retinal Vein Occlusion Treatment Market, by Central Retinal Vein Occlusion (CRVO), 2018 - 2030 (USD Million)
  • Fig. 16 Global Retinal Vein Occlusion Treatment Market, by Branch Retinal Vein Occlusion (BRVO), 2018 - 2030 (USD Million)
  • Fig. 17 Global Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
  • Fig. 18 Global Retinal Vein Occlusion Treatment Market, by Anti-vascular Endothelial Growth Factor (Anti-VEGF), 2018 - 2030 (USD Million)
  • Fig. 19 Global Retinal Vein Occlusion Treatment Market, by Corticosteroid Drugs, 2018 - 2030 (USD Million)
  • Fig. 20 Global Retinal Vein Occlusion Treatment Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 21 Global Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
  • Fig. 22 Global Retinal Vein Occlusion Treatment Market, by Hospital & Clinics 2018 - 2030 (USD Million)
  • Fig. 23 Global Retinal Vein Occlusion Treatment Market, by Retail Pharmacy 2018 - 2030 (USD Million)
  • Fig. 24 Global Retinal Vein Occlusion Treatment Market, by Others, 2018 - 2030 (USD Million)
  • Fig. 25 Regional Marketplace: Key Takeaways
  • Fig. 26 Regional Outlook, 2022 & 2030
  • Fig. 27 Global Retinal Vein Occlusion Treatment Market: Region Movement Analysis
  • Fig. 28 North America Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 30 Canada Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 32 Germany Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 33 UK Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 34 France Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 37 Denmark Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 38 Sweden Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 42 China Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 43 India Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 44 Australia Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 46 Thailand Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 50 Argentina Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 51 Middle East and Africa Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 52 South Africa Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 53 Saudi Arabia Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 54 UAE Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
  • Fig. 55 Kuwait Retinal Vein Occlusion Treatment Market, 2018 - 2030 (USD Million)
目次
Product Code: GVR-4-68040-122-1

Retinal Vein OcclusionTreatment Market Growth & Trends:

The global retinal vein occlusion treatment market size is expected to reach USD 4.18 billion by 2030, growingat a CAGR of 6.92% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Growing prevalence of eye diseases, increasing geriatric population, coupled with rising awareness about ophthalmic disease treatment are the key factors boosting the market growth. The presence of already existing products or approved products and a strong product pipeline are factors anticipated to fuel the market growth. Furthermore, the increasing prevalence of diabetes and atherosclerosis may increase the prevalence of RVO and positively impact the market during the study period. Rising approval of novel drugs for RVO is expected to offer lucrative opportunities for the market during the study period.

Samsung Bioepis developed the first biosimilar drug Byooviz (ranibizumab-nuna) for the treatment of retinal disorders, such as macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, and RVO. In September 2020, the drug was approved by the FDA for commercialization. However, the high cost associated with drugs may limit the prescription of drugs and hinder market growth. According to a 2021 study published in BMC Ophthalmology, the treatment of central RVO(CRVO) and branch RVO (BRVO) with ranibizumab costs approximately USD 449.17 and USD 454.75 per quality-adjusted life year (QALY) in China. Therefore, the introduction of affordable drugs with high efficacy and safety is expected to create new growth opportunities for the market during the projected timeframe.

Moreover, conditions, such as diabetic retinopathy, cataract, glaucoma, and age-related macular degeneration, are major causes of the disorder globally. A rise in the elderly population is creating a proportionate increase in number of people suffering from RVO. In addition, lifestyle changes have also resulted in increased incidence of various diseases causing RVO, such as cardiovascular diseases & hypertension. According to the Lancet Global Health Commission's report on global eye health, it was estimated that in 2020, 510 million people worldwide had uncorrected close vision impairment, and 596 million people worldwide had uncorrected distance vision impairment. Thus, the increasing prevalence of secondary conditions may increase the prevalence of RVO and support market growth.

Retinal Vein Occlusion Treatment Market Report Highlights:

  • By disease type, the branch segment dominated themarket in 2022 owing to the increasing focus on R&D activities and investments to develop novel drugs for efficient treatment
  • By treatment, anti-vascular endothelial growth factor (Anti-VEGF) segment held the largest share in 2022 owing to their safety and universal acceptance as the first-line treatment option
  • The retail pharmacy end-user segment held the largest share in 2022 due to factors, such as improved accessibility of medication and available options for RVO through retail pharmacies
  • North America established a strong regional position with a 41.2% share in 2022. This is a result of the region's extensive R&D activities due to increased government funding and a high adoption rate of treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation
    • 1.1.1. Market Definitions
  • 1.2. Objectives
    • 1.2.1. Objective - 1
    • 1.2.2. Objective - 2
    • 1.2.3. Objective - 3
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Abbreviations
  • 1.10. List of Primary Sources

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Disease Type and Treatment Snapshot
  • 2.3. End-user Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers
    • 3.4.1. Increasing prevalence of retinal diseases
    • 3.4.2. Rising geriatric population
    • 3.4.3. Presence of strong product portfolio
  • 3.5. Market Restraint Analysis
    • 3.5.1. Lack of awareness and underdiagnoses of the disease
    • 3.5.2. High cost of the treatment
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis
    • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Disease Type Business Analysis

  • 4.1. Retinal Vein Occlusion Treatment market: Disease Type Movement Analysis
  • 4.2. Central Retinal Vein Occlusion (CRVO)
    • 4.2.1. Central Retinal Vein Occlusion (CRVO) Market, 2018 - 2030 (USD Million)
  • 4.3. Branch Retinal Vein Occlusion (BRVO)
    • 4.3.1. Branch Retinal Vein Occlusion (BRVO) Market, 2018 - 2030 (USD Million)

Chapter 5. Treatment Business Analysis

  • 5.1. Retinal Vein Occlusion Treatment Market: Treatment Movement Analysis
  • 5.2. Anti-vascular Endothelial Growth Factor (Anti-VEGF)
    • 5.2.1. Anti-vascular Endothelial Growth Factor (Anti-VEGF) Market, 2018 - 2030 (USD Million)
  • 5.3. Corticosteroid Drugs
    • 5.3.1. Corticosteroid Drugs Market, 2018 - 2030 (USD Million)
  • 5.4. Others
    • 5.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. End-user Business Analysis

  • 6.1. Retinal Vein Occlusion Treatment Market: End-user Movement Analysis
  • 6.2. Hospital & Clinics
    • 6.2.1. Hospital & Clinics Market, 2018 - 2030 (USD Million)
  • 6.3. Retail Pharmacy
    • 6.3.1. Retail Pharmacy Market, 2018 - 2030 (USD Million)
  • 6.4. Others
    • 6.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Regional Business Analysis

  • 7.1. Retinal Vein Occlusion Treatment Market Share By Region, 2022 & 2030
  • 7.2. North America
    • 7.2.1. North America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Target Disease Prevalence
      • 7.2.2.3. Competitive Scenario
      • 7.2.2.4. Regulatory Framework
      • 7.2.2.5. Reimbursement Scenario
      • 7.2.2.6. U.S. Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD MILLION)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Target Disease Prevalence
      • 7.2.3.3. Competitive Scenario
      • 7.2.3.4. Regulatory Framework
      • 7.2.3.5. Reimbursement Scenario
      • 7.2.3.6. Canada Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Target Disease Prevalence
      • 7.3.2.3. Competitive Scenario
      • 7.3.2.4. Regulatory Framework
      • 7.3.2.5. Reimbursement Scenario
      • 7.3.2.6. Germany Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Target Disease Prevalence
      • 7.3.3.3. Competitive Scenario
      • 7.3.3.4. Regulatory Framework
      • 7.3.3.5. Reimbursement Scenario
      • 7.3.3.6. UK Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Target Disease Prevalence
      • 7.3.4.3. Competitive Scenario
      • 7.3.4.4. Regulatory Framework
      • 7.3.4.5. Reimbursement Scenario
      • 7.3.4.6. France Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Target Disease Prevalence
      • 7.3.5.3. Competitive Scenario
      • 7.3.5.4. Regulatory Framework
      • 7.3.5.5. Reimbursement Scenario
      • 7.3.5.6. Italy Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Target Disease Prevalence
      • 7.3.6.3. Competitive Scenario
      • 7.3.6.4. Regulatory Framework
      • 7.3.6.5. Reimbursement Scenario
      • 7.3.6.6. Spain Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Target Disease Prevalence
      • 7.3.7.3. Competitive Scenario
      • 7.3.7.4. Regulatory Framework
      • 7.3.7.5. Reimbursement Scenario
      • 7.3.7.6. Denmark Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Target Disease Prevalence
      • 7.3.8.3. Competitive Scenario
      • 7.3.8.4. Regulatory Framework
      • 7.3.8.5. Reimbursement Scenario
      • 7.3.8.6. Sweden Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Target Disease Prevalence
      • 7.3.9.3. Competitive Scenario
      • 7.3.9.4. Regulatory Framework
      • 7.3.9.5. Reimbursement Scenario
      • 7.3.9.6. Norway Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Competitive Scenario
      • 7.4.2.4. Regulatory Framework
      • 7.4.2.5. Reimbursement Scenario
      • 7.4.2.6. Japan Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Competitive Scenario
      • 7.4.3.4. Regulatory Framework
      • 7.4.3.5. Reimbursement Scenario
      • 7.4.3.6. China Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Competitive Scenario
      • 7.4.4.4. Regulatory Framework
      • 7.4.4.5. Reimbursement Scenario
      • 7.4.4.6. India Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Target Disease Prevalence
      • 7.4.5.3. Competitive Scenario
      • 7.4.5.4. Regulatory Framework
      • 7.4.5.5. Reimbursement Scenario
      • 7.4.5.6. South Korea Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Target Disease Prevalence
      • 7.4.6.3. Competitive Scenario
      • 7.4.6.4. Regulatory Framework
      • 7.4.6.5. Reimbursement Scenario
      • 7.4.6.6. Australia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Target Disease Prevalence
      • 7.4.7.3. Competitive Scenario
      • 7.4.7.4. Regulatory Framework
      • 7.4.7.5. Reimbursement Scenario
      • 7.4.7.6. Thailand Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Competitive Scenario
      • 7.5.2.4. Regulatory Framework
      • 7.5.2.5. Reimbursement Scenario
      • 7.5.2.6. Brazil Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.3. Mexico
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Competitive Scenario
      • 7.5.3.4. Regulatory Framework
      • 7.5.3.5. Reimbursement Scenario
      • 7.5.3.6. Mexico Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.5.4. Argentina
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Competitive Scenario
      • 7.5.4.4. Regulatory Framework
      • 7.5.4.5. Reimbursement Scenario
      • 7.5.4.6. Argentina Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Competitive Scenario
      • 7.6.2.4. Regulatory Framework
      • 7.6.2.5. Reimbursement Scenario
      • 7.6.2.6. South Africa Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Competitive Scenario
      • 7.6.3.4. Regulatory Framework
      • 7.6.3.5. Reimbursement Scenario
      • 7.6.3.6. Saudi Arabia Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Competitive Scenario
      • 7.6.4.4. Regulatory Framework
      • 7.6.4.5. Reimbursement Scenario
      • 7.6.4.6. UAE Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Competitive Scenario
      • 7.6.5.4. Regulatory Framework
      • 7.6.5.5. Reimbursement Scenario
      • 7.6.5.6. Kuwait Retinal Vein Occlusion Treatment market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant's overview
  • 8.2. Financial performance
  • 8.3. Participant categorization
    • 8.3.1. Market Leaders
    • 8.3.2. Retinal Vein Occlusion Treatment market Share Analysis, 2022
    • 8.3.3. Company Profiles
      • 8.3.3.1. AbbVie Inc
      • 8.3.3.1.1. Company Overview
      • 8.3.3.1.2. Financial Performance
      • 8.3.3.1.3. Product Benchmarking
      • 8.3.3.1.4. Strategic Initiatives
      • 8.3.3.2. F. Hoffmann-La Roche Ltd
      • 8.3.3.2.1. Company Overview
      • 8.3.3.2.2. Financial Performance
      • 8.3.3.2.3. Product Benchmarking
      • 8.3.3.2.4. Strategic Initiatives
      • 8.3.3.3. Regeneron Pharmaceuticals Inc
      • 8.3.3.3.1. Company Overview
      • 8.3.3.3.2. Financial Performance
      • 8.3.3.3.3. Product Benchmarking
      • 8.3.3.3.4. Strategic Initiatives
      • 8.3.3.4. Taiwan Liposome Company, Ltd
      • 8.3.3.4.1. Company Overview
      • 8.3.3.4.2. Financial Performance
      • 8.3.3.4.3. Product Benchmarking
      • 8.3.3.4.4. Strategic Initiatives
      • 8.3.3.5. Aerie Pharmaceuticals Inc
      • 8.3.3.5.1. Company Overview
      • 8.3.3.5.2. Financial Performance
      • 8.3.3.5.3. Product Benchmarking
      • 8.3.3.5.4. Strategic Initiatives
      • 8.3.3.6. CalciMedica Inc
      • 8.3.3.6.1. Company Overview
      • 8.3.3.6.2. Financial Performance
      • 8.3.3.6.3. Product Benchmarking
      • 8.3.3.6.4. Strategic Initiatives
      • 8.3.3.7. Outlook Therapeutics, Inc
      • 8.3.3.7.1. Company Overview
      • 8.3.3.7.2. Financial Performance
      • 8.3.3.7.3. Product Benchmarking
      • 8.3.3.7.4. Strategic Initiatives
      • 8.3.3.8. Kodiak Sciences Inc
      • 8.3.3.8.1. Company Overview
      • 8.3.3.8.2. Financial Performance
      • 8.3.3.8.3. Product Benchmarking
      • 8.3.3.8.4. Strategic Initiatives
      • 8.3.3.9. Chugai Pharmaceutical Co., Ltd
      • 8.3.3.9.1. Company Overview
      • 8.3.3.9.2. Financial Performance
      • 8.3.3.9.3. Product Benchmarking
      • 8.3.3.9.4. Strategic Initiatives
      • 8.3.3.10. Pfizer Inc
      • 8.3.3.10.1. Company Overview
      • 8.3.3.10.2. Financial Performance
      • 8.3.3.10.3. Product Benchmarking
      • 8.3.3.10.4. Strategic Initiatives
    • 8.3.4. Strategy Mapping
      • 8.3.4.1. Expansion
      • 8.3.4.2. Acquisition
      • 8.3.4.3. Collaborations
      • 8.3.4.4. Disease Type/Drug Class Launch
      • 8.3.4.5. Partnerships
      • 8.3.4.6. Others